Showing 1 - 10 of 14 Blood and Lymph Conditions
A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia

Status: Enrolling

Investigator: Shilpan Shah

Study Coordinator: Britney Nguyen

Phone: 713.441.0685

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of bleximenib in phase 1 (Part 1 [Dose Escalation] and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion). The purpose of the Ph ... Read more >

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Status: Open Not Enrolling

Investigator: Siddhartha Ganguly

Study Coordinator: Danielle Sewall

Phone: 346.238.2674

The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab i ... Read more >

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma

Status: Enrolling

Investigator: Siddhartha Ganguly

Study Coordinator: Britney Nguyen

Phone: 713.441.0685

The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexametha ... Read more >

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants with DLBCL

Status: Open Not Enrolling

Investigator: Sai ravi kiran Pingali

Study Coordinator:

Phone:

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of this study is to assess the change in disease activity of epcoritamab when combined with intraven ... Read more >

Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia (ASC2ESCALATE)

Status: Open Not Enrolling

Investigator: Shilpan Shah

Study Coordinator: Danielle Sewall

Phone: 346.238.2674

This will be a multicenter Phase II open-label study of asciminib in CML-CP patients who have been previously treated with one prior ATP- binding site TKI with discontinuation due to treatment failure, warning or intolerance. (2L patient cohort) ... Read more >

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

Status: Enrolling

Investigator: Carrie Yuen

Study Coordinator: Britney Nguyen

Phone: 713.441.0685

This phase III trial compares the effect of adding a stem cell transplant with melphalan after completing chemotherapy with daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD) versus chemotherapy with Dara-VCD alone for treati ... Read more >

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

Status: Enrolling

Investigator: Siddhartha Ganguly

Study Coordinator: Britney Nguyen

Phone: 713.441.0685

This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell [CAR-T] therapy) for multiple myeloma. The ... Read more >

Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial (LeAAPS)

Status: Enrolling

Investigator: Ross Reul

Study Coordinator: Deena Victor

Phone: 713.441.4536

This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or syst ... Read more >

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Status: Enrolling

Investigator: Siddhartha Ganguly

Study Coordinator: Danielle Sewall

Phone: 346.238.2674

The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). ... Read more >

Open Label, Multi-center, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR BCMA T Cells (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

Status: Open Not Enrolling

Investigator: Siddhartha Ganguly

Study Coordinator: Danielle Grbavac

Phone: 346.238.4456

A phase 1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma. ... Read more >

Phase IB/II Study Combining All-Trans Retinoic Acid (ATRA) with Carfilzomib Based Therapy in Plasma Cell Myeloma Patients Refractory to Carfilzomib

Status: Enrolling

Investigator: Sai ravi kiran Pingali

Study Coordinator: Danielle Grbavac

Phone: 346.238.4456

This is a Phase IB/II trial that will investigate the safety, tolerability and efficacy of combination therapy using All-Trans Retinoic Acid (ATRA) with Carfilzomib based therapies in plasma cell myeloma also commonly referred as Multiple Myelom ... Read more >

Sample and Data Collection for Hematologic disorders section, Houston Methodist Cancer Center

Status: Open Not Enrolling

Investigator: Sai ravi kiran Pingali

Study Coordinator: Natolie Hamilton

Phone: 469.267.9275

This is a laboratory-based study supported by NIH funding. It is aimed to explore the therapeutic effects of novel molecules or antigens to treat hematologic diseases. In order to complete these studies, samples including peripheral blood, bone ... Read more >

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Status: Enrolling

Investigator: Shilpan Shah

Study Coordinator: Danielle Grbavac

Phone: 346.238.4456

This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with ... Read more >

The International PNH Interest Group PNH Registry

Status: Open Not Enrolling

Investigator: Lawrence Rice

Study Coordinator: Melissa Whipple

Phone: 713.441.3247

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare condition. Prospective longitudinal data in large populations are limited. The aim of this International PNH Interest Group (IPIG) registry is to develop an international database to prospec ... Read more >